Australian researchers want to provide nasal spray COVID-19 vaccine

Australian researchers say that a breakthrough in COVID-19 vaccination can be achieved around the world, boosting research into administering drugs via nasal drops, so nurses will eventually put a syringe in place. can do.

The New South Wales (NSW) government has provided 100,000 needle-free COVID-19 vaccines to Professor Daniela Traini of Macquarie University and Professor Paul Sodason of NSW University, a core member of the NSW RNA Vaccine Production and Research Network. I gave a dollar grant.

They will work with Sydney-based biotechnology company Medlab to investigate the use of nanotechnology to provide the same approved vaccine.

Traini said her challenge was to ensure that the vaccine was intact and fully functional in the nasal passages.

Epoch Times Photo
Professor Daniela Tolejny. (Macquarie University / Attached)

“Current mRNA vaccines like Pfizer and Moderna are delivered by intramuscular injection and have special refrigeration requirements,” Traini said.

Alternative injections can reduce the fear of needles that are often prevalent in many people, especially as Australia recently approved COVID vaccination for children up to the age of five.

Last month, the rollout of vaccinations to 2.3 million children aged 5 to 11 in Australia began before returning to school.

“It may not be necessary to refrigerate the vaccine in this condition, which is very important for people in remote areas without electricity, where it is difficult to store the frozen vaccine at the required negative temperature. I see. 70 degrees Celsius, “Traini said.

“If this is the case, it could be a game changer not only for remote Australian communities, but also for countries in the Third World.

Vaccine nasal spray delivery will also address the shortage of hospital staff.

“Trained personnel no longer need to be vaccinated, reducing medical waste and reducing pressure on health care workers,” she said.

Nasal sprays are not a new technology as before, and influenza vaccines are already successfully administered in the same way. In addition, other vaccines such as polio and rotavirus are offered as oral drops.

“Oral drops have no effect on mRNA vaccines because they are broken down by the digestive process before they are effective,” Traini said.

The study is expected to take half a year, and if successful, the study will continue.

Research is underway in countries around the world to develop nasal drops that help prevent and treat COVID-19, especially given that the nasal lining has been identified as an important entry point for the virus.

In a study on a similar product, Australia-based company Starpharma argued that the nasal spray Viraleze could inactivate more than 99.9% of the COVID-19 virus in 30 seconds.

According to the company, Viraleze “inactivates the virus by blocking the interaction between the viral surface protein and the human cell receptor protein.”

Viraleze is not yet approved by Therapeutic Goods Administration (TGA) in Australia, but is available in Europe, India, and seven other countries. TGA fine Starpharma advertised the product to Australian consumers last year, but it wasn’t approved yet, so it was $ 93,240 ($ 68,863).

Jesse Chan


Jessie Zhang is a Sydney-based journalist who reports on Australian news. She holds a bachelor’s degree in commerce and music. Contact her at [email protected]

Posted on